Remix Therapeutics reveals unprecedented insights into RNA alternative splicing regulation through RNA sequencing

Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying drivers of disease, today announced the publication of a collaborative research study with Prof. Juan Valcárcel at the Center for Genomic Regulation in Barcelona, Spain in the prestigious journal Science. The research article, titled “Transcriptome-wide splicing network reveals specialized regulatory …